Retatrutide, a groundbreaking dual-acting glucose-responsive incretin mimetic, represents a significant advance in peptide therapeutics for the handling of type 2 diabetes and, increasingly, obesity. Unlike many existing therapeutic interventions, retatrutide merges the actions of a GLP-1 receptor activator and a GIP receptor agonist, offering a mo